ABOS241220C2500
- 0.20
- +0.10+100.00%
Acumen Pharmaceuticals Newsroom
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $15
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Acumen Pharmaceuticals (ABOS)
Stifel Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $10
Acumen Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $15
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
Strong Buy Rating for Acumen Pharmaceuticals Amid Promising Trial Results for Lead Candidate ACU193
Acumen Pharmaceuticals Analyst Ratings
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $15
Buy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer's Treatment Advances and Strong Financials
Acumen Pharmaceuticals Analyst Ratings
Citigroup Starts Acumen Pharmaceuticals With Buy Rating, $7 Price Target
Acumen Pharmaceuticals Price Target Announced at $7.00/Share by Citigroup
Acumen Pharmaceuticals Analyst Ratings
Citi Initiates Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Announces Target Price $7
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Buy Rating Justified: Acumen Pharmaceuticals' Promising Position in Alzheimer's Treatment Market
Acumen Pharmaceuticals' Sabirnetug: A Novel Approach in Alzheimer's Disease Treatment Warrants a Buy Rating